Evidence map›Paper›PMID 33163054›Full record

SynthesisAfrican health sciences2020

Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis.

Shanshan Wu, Yanhai Wang, Jiaojiao Zhang, Bo Han, Baishan Wang, Wanli Gao, Ning Zhang, Cheng Zhang, Feng Yan, Zhijing Li

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in African health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Therapeutic Antibodies in Medicine.Molecules (Basel, Switzerland) · 2023
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shanshan WuClinical Laboratory Department, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, No. 33 Beiling Street, Huanggu District, Shenyang, 110032, Liaoning, China.
Yanhai WangClinical Laboratory Department, Dong Sheng People's Hospital of Ordos, Ordos, 017000, The Inner Mongolia Autonomous Region, China.
Jiaojiao ZhangClinical Laboratory Department, The Fourth Affiliated Hospital of China Medical University, No. 4 Chongshan Road, Huanggu District, Shenyang, 110032, Liaoning, China.
Bo HanClinical Laboratory Department, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, No. 33 Beiling Street, Huanggu District, Shenyang, 110032, Liaoning, China.
Baishan WangClinical Laboratory Department, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, No. 33 Beiling Street, Huanggu District, Shenyang, 110032, Liaoning, China.
Wanli GaoClinical Laboratory Department, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, No. 33 Beiling Street, Huanggu District, Shenyang, 110032, Liaoning, China.
Ning ZhangClinical Laboratory Department, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, No. 33 Beiling Street, Huanggu District, Shenyang, 110032, Liaoning, China.
Cheng ZhangClinical Laboratory Department, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, No. 33 Beiling Street, Huanggu District, Shenyang, 110032, Liaoning, China.
Feng YanClinical Laboratory Department, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, No. 33 Beiling Street, Huanggu District, Shenyang, 110032, Liaoning, China.
Zhijing LiClinical Laboratory Department, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, No. 33 Beiling Street, Huanggu District, Shenyang, 110032, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGiven the inconsistency of previous studies and the newly emerging evidence, we decided to conduct a meta-analysis.

methodsThe meta-analysis included 2 randomized controlled trials and 13 observational studies 742 patients in total. Qualified studies were properly searched from databases . Data were analyzed by the RevMan 5.3 software. Results were demonstrated as WMD , SMD and RR with 95% CIs, I

resultswe observed that a remarkable increase of complement C3 in the rituximab group than placebo group (WMDfixed= 7.67mg/dL, 95%CIs=-0.16~15.50, I

conclusionalthough the efficacy of rituximab is highly controversial for SLE, our study shows that rituximab presents a satisfying efficacy and safety for SLE.

Indexed as

AdultFemaleHumansImmunologic FactorsImmunosuppressive AgentsLupus Erythematosus, SystemicMaleRituximabTreatment OutcomeImmunologic FactorsImmunosuppressive AgentsRituximabEfficacymeta-analysisrituximabsafetysystemic lupus erythematosus

Identifiers

PMID33163054
PMCPMC7609121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.